Ischemic stroke
Conditions
Interventions
Experimental group:Cord blood mononuclear cells were infused on the basis of standardized treatment
Control group:Placebo infusion was performed on the basis of standardized treatment
Sponsors
The Second People's Hospital of Shandong
Eligibility
Sex/Gender
All
Age
35 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. Aged 35 to 75 years old; 2. Subacute stage of ischemic stroke (1-3 months after stroke); 3. Brain imaging showed ischemic lesions in the anterior circulation; 4. NIHSS score: 7-21; 5. Able to receive or carry out neurological evaluation and rehabilitation treatment; 6. Patients or family members gave informed consent and signed the informed consent form.
Exclusion criteria
Exclusion criteria: 1. Hemorrhagic stroke or symptomatic hemorrhagic transformation; 2. Mrs score > 2 before onset, and the condition deteriorated within 72 hours before enrollment (NIHSS score increased by 4 or more); 3. Chronic liver disease, liver and kidney dysfunction, elevated ALT (3 times higher than the upper limit of normal value), elevated serum creatinine (2 times higher than the upper limit of normal value); 4. Severe cardiopulmonary disease or malignant tumor, and the researcher believes that it is not suitable to participate in this study; 5. Patients whose life expectancy is less than 12 months or who are unable to complete the study for other reasons; 6. Those who have a history of drug or food allergy and are known to be allergic to the drug components of this study; 7. Women of childbearing age who have negative pregnancy test but refuse to take effective contraceptive measures; Pregnant or lactating women; 8. Participate in clinical studies of other investigational drugs within the last 30 days; 9. Inability to understand and / or comply with the study procedures and / or follow-up due to mental illness, cognitive or emotional disorders; 10. It is associated with other autoimmune diseases such as active stage, pulmonary infection or other systemic acute infectious diseases. Human immunodeficiency virus (HIV), human T-cell leukemia virus (HTLV), hepatitis B virus (HBV) and hepatitis C virus (HCV) were positive.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| ModifiedRankin Scale, mRS; | — |
Secondary
| Measure | Time frame |
|---|---|
| National Institute of Health stroke scale, NIHSS;Fugl-Meyer Assessment;Mini-Mental State Examination, MMSE;EuroQol (Quality of life) - 5 Dimensions, EQ-5D;Barthel Index;Peripheral blood CRP;erythrocyte sedimentation rate;Hemagglutination;Blood homocysteine;TNF-a;IL-1ß;IL-6; | — |
Countries
China
Contacts
Public ContactZhang Qinghua
The Second People's Hospital of Shandong
Outcome results
None listed